


concentration of test sample required to clot a given volume of factor IX-deficient plasma in a given time by the kaolin-cephalin method divided by the concentration of the factor IX protein in the test sample as determined by ELISA, of at least 90% of that of average normal human plasma.

2 34. A preparation according to claim 33, wherein said factor IX protein has a specific activity of 100%.

3 35. A method of treating a human patient suffering from a deficiency of factor IX, said method comprising the step of administering to said patient a plasma-free preparation comprising as active ingredient a biologically active recombinant DNA-derived factor IX protein derived from a single human individual which (1) essentially has the amino acid sequence of human factor IX protein, (2) is free from contamination by poxviruses and by all ^{human} plasma constituents, and (3) has a specific activity defined as the concentration of test sample required to clot a given volume of factor IX-deficient plasma in a given time by the kaolin-cephalin method divided by the concentration of factor IX protein in the test sample as determined by ELISA, of at least 90% of that of average normal human plasma.

4 36. A method according to claim 35, wherein said factor IX protein has a specific activity of 100%. 

32